Pegaspargase
Brand names: Oncaspar · Active ingredient: Pegaspargase
In short: ONCASPAR® is indicated as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of pediatric and adult patients with ALL. ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with ALL and hyperse
What is Pegaspargase used for?
ONCASPAR® is indicated as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of pediatric and adult patients with ALL.
ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with ALL and hypersensitivity to native forms of L-asparaginase.
Pegaspargase dosage
Patients 21 Years of Age or Younger
The recommended dose of ONCASPAR for patients up to and including 21 years of age is 2,500 International Units/m2 intramuscularly or intravenously no more frequently than every 14 days.
Patients More Than 21 Years of Age
The recommended dose of ONCASPAR for adult patients more than 21 years of age is 2,000 International Units/m2 intramuscularly or intravenously no more frequently than every 14 days.
Premedicate patients with acetaminophen, an H-1 receptor blocker (such as diphenhydramine), and an H-2 receptor blocker (such as famotidine) 30-60 minutes prior to administration of ONCASPAR to decrease the risk and severity of both infusion and hypersensitivity reactions .
Monitor patients at least weekly, with bilirubin, transaminases, glucose and clinical examinations until recovery from the cycle of therapy. If an adverse reaction should occur, modify treatment according to Table 1.
Adverse Reaction | SeverityGrade 1 is mild, grade 2 is moderate, grade 3 is severe, and grade 4 is life-threatening. | Action
Infusion Reaction/Hypersensitivity Reaction | Grade 1 | Reduce the infusion rate by 50%
Grade 2 | Interrupt the infusion of ONCASPAR
Treat the symptoms
When symptoms resolve, resume the infusion and reduce the infusion rate by 50%
Grade 3 to 4 | Discontinue ONCASPAR permanently
Thrombosis | Uncomplicated deep vein thrombosis | Hold ONCASPAR
Treat with appropriate antithrombotic therapy
Upon resolution of symptoms consider resuming ONCASPAR, while continuing antithrombotic therapy
Severe or life-threatening thrombosis | Discontinue ONCASPAR permanently
Treat with appropriate antithrombotic therapy
Pancreatitis | Grades 3 to 4 | Hold ONCASPAR for elevations in lipase or amylase >3 × ULN until enzyme levels stabilize or are declining
Discontinue ONCASPAR permanently if clinical pancreatitis is confirmed
Hemorrhage | Grade 3 to 4 | Hold ONCASPAR
Evaluate for coagulopathy and consider clotting factor replacement as needed
Resume ONCASPAR with the next scheduled dose if bleeding is controlled
Hepatotoxicity | Total bilirubin more than 3 times to no more than 10 times the ULN | Hold ONCASPAR until total bilirubin is ≤1.5 times the ULN
Total bilirubin more than 10 times the ULN | Discontinue ONCASPAR and do not make up for missed doses
Administer ONCASPAR in a healthcare setting with appropriate medical support and resuscitation equipment to manage hypersensitivity reactions, should they occur .
ONCASPAR is a clear and colorless solution. Visually inspect parenteral drug products for particulate matter, cloudiness, or discoloration prior to administration. If any of these are present, discard the vial.
When ONCASPAR is administered intramuscularly:
Limit the volume at a single injection site to 2 mL. …
How to take Pegaspargase — instructions & advice from the label
Anaphylaxis and Serious Hypersensitivity Reactions
Inform patients of the possibility of serious allergic reactions, including anaphylaxis, and to seek immediate medical care for any swellings or difficulty breathing .
Thrombosis
Instruct patients on the risk of thrombosis and hemorrhage and to seek immediate medical attention if they experience severe headache, arm or leg swelling, shortness of breath, or chest pain .
Pancreatitis
Instruct patients on the signs and symptoms of pancreatitis and to seek immediate medical attention if they experience severe abdominal pain .
Glucose Intolerance
Instruct patients on the risk of hyperglycemia and glucose intolerance. Advise patients to immediately report excessive thirst or increase in the volume or frequency of urination .
Hemorrhage
Advise patients to report any unusual bleeding or bruising to their healthcare provider .
Hepatotoxicity, including Veno-Occlusive Liver Disease (VOD)
Inform patients that liver problems, including severe, life-threatening, or fatal VOD and abnormalities in liver tests, may develop during ONCASPAR treatment. …
Warnings & precautions
Do not take this medicine if: ONCASPAR is contraindicated in patients with a:
History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR or to any of the excipients .
History of serious thrombosis with prior L-asparaginase therapy .
History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy .
History of serious hemorrhagic events with prior L-asparaginase therapy .
Severe hepatic impairment .
Anaphylaxis and serious hypersensitivity reactions can occur in patients receiving ONCASPAR. The risk of serious hypersensitivity reactions is higher in patients with known hypersensitivity to (E.) coli derived L-asparaginase formulations. Other hypersensitivity reactions can include angioedema, lip swelling, eye swelling, erythema, blood pressure decreased, bronchospasm, dyspnea, pruritus, and rash .
Premedicate patients 30-60 minutes prior to administration of ONCASPAR. . Observe patients for 1 hour after administration of ONCASPAR in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (for example, epinephrine, oxygen, intravenous steroids, antihistamines) . Discontinue ONCASPAR in patients with serious hypersensitivity reactions.
Serious thrombotic events, including sagittal sinus thrombosis can occur in patients receiving ONCASPAR . Discontinue ONCASPAR in patients with serious thrombotic events .
Pancreatitis can occur in patients receiving ONCASPAR. Hemorrhagic or necrotizing pancreatitis with fatal outcomes have been reported . Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Assess serum amylase and/or lipase levels to confirm early signs of pancreatic inflammation. Discontinue ONCASPAR in patients where pancreatitis is suspected. If pancreatitis is confirmed, do not resume ONCASPAR . …
Pegaspargase side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Anaphylaxis and serious hypersensitivity reactions
Thrombosis
Pancreatitis
Glucose intolerance
Hemorrhage
Hepatotoxicity, including VOD
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.
The most common grade 3 and 4 adverse reactions (>5%) included: hypoalbuminemia, elevated transaminase, febrile neutropenia, hypertriglyceridemia, hyperglycemia, bilirubin increased, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, and infections.
First-Line Treatment of Acute Lymphoblastic Leukemia (ALL)
Study CCG-1962 was a randomized (1:1), active controlled study that enrolled 118 patients, with a median age of 4.7 years (1.1-9.9 years), of whom 54% were males and 65% White, 14% Hispanic, 8% Black, 8% Asian, and 6% other race. Of the 59 patients in Study 1 who were randomized to ONCASPAR, 48 patients (81%) received all 3 planned doses of ONCASPAR, 6 (10%) received 2 doses, 4 (7%) received 1 dose, and 1 patient (2%) did not receive the assigned treatment. …
Drug interactions
Pegaspargase may increase the risk of glucocorticoid-induced toxicities, including osteonecrosis through a potential increase in exposure of dexamethasone .
About this medicine
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine specific enzyme. L-asparaginase is a tetrameric enzyme that is produced endogenously by E. coli and consists of identical 34.5 kDa subunits. Approximately 69 to 82 molecules of mPEG are linked to L-asparaginase; the molecular weight of each mPEG molecule is about 5 kDa. ONCASPAR activity is expressed in International Units.
ONCASPAR (pegaspargase) injection is supplied as a clear, colorless, preservative-free, isotonic sterile solution in phosphate-buffered saline, pH 7.3, for intramuscular use or for dilution prior to intravenous infusion. Each vial of ONCASPAR contains 3,750 International Units of pegaspargase in 5 mL of solution. Each milliliter contains 750 International Units of pegaspargase, dibasic sodium phosphate, USP (5.58 mg), monobasic sodium phosphate, USP (1.20 mg), and Sodium Chloride, USP (8.50 mg) in Water for Injection, USP. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ac7b6a6f-6ddb-48c6-8088-d8a8e3fea6ce. Read the full official label on DailyMed.